Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension

Journal of Hypertension

Volumn 22, Issue 3, 2004, Pages 593-603

  Rasoul, Saman ^b   Carretero, Oscar A ^a   Peng, Hongmei ^a   Cavasin, Maria A ^a   Zhuo, Jialong ^a   Sanchez Mendoza, Alicia ^c   Brigstock, David R ^d   Rhaleb, Nour Eddine ^a  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Institudo Natl Cardiol Ignacio C   (Mexico)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibitor; Collagen; Heart; Hypertension; Inflammation; N acetyl seryl aspartyl lysyl proline (Ac SDKP)

Indexed keywords

ANGIOTENSIN; ANTIFIBRINOLYTIC AGENT; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SERASPENIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEMATOPOIETIC STEM CELL; HYPERTENSION; INFLAMMATORY CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 1642304000     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200403000-00023     Document Type: Article

References (59)

1. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci USA 1989; 86:779-782.
2. Bonnet D, Lemoine FM, Pontvert-Delucq S, Baillou C, Najman A, Guigon M. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp- Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulabpopulations in response to growth factors. Blood 1993; 82:3307-3314.
3. Pradelles P, Frobert Y, Créminon C, Liozon E, Massé A, Frindel E. Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun 1990; 170:986-993.
4. Pradelles P, Frobert Y, Créminon C, Ivonine H, Frindel E. Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin b4 in mouse tissues. FEBS Lett 1991; 289:171-175.
5. Azizi M, Rousseau A, Ezan E, Guyene T-T, Michelet S, Grognet JM, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97:839-844.
6. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 1997; 30:1015-1019.
7. Rhaleb N-E, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension 2001; 37:827-832.
8. Pokharel S, Rasoul S, Roks AJM, Van Leeuwen REW, Van Luyn MJA, Deelman LE, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 2002; 40:155-161.
9. Rhaleb N-E, Peng H, Yang X-P, Liu Y-H, Mehta D, Ezan E, et al. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation 2001; 103:3136-3141.
10. Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb N-E. Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 2001; 37:794-800.
11. Liu Y-H, Yang X-P, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Infest 1997; 99:1926-1935.
12. Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM, Conrad, CH. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997; 96: 4002-4010.
13. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993; 122:395-403.
14. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol 1995; 27: 1545-1560.
15. Panizo A, Pardo Mindán FJ, Galindo MF, Cenarruzabeitia E, Hernández M, Díez J. Are mast cells involved in hypertensive heart disease? J Hypertens 1995; 13:1201-1208.
16. Hocher B, Godes M, Olivier J, Weil J, Eschenhagen T, Slowinski T, et al. Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens 2002; 20:745-751.
17. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-β1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997; 29:1947-1958.
18. Kothapalli D, Hayashi N, Grotendorst GR. Inhibition of TGF-β-stimulated CTGF gene expression and anchorage-independent growth by cAMP identifies a CTGF-dependent restriction point in the cell cycle. FASEB J 1998; 12:1151-1161.
19. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000; 32:1805-1819.
20. Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res 1994; 74:727-739.
21. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995; 147: 325-338.
22. Chiariello M, Ambrosio G, Cappelli-Bigazzi M, Perrone-Filardi P, Brigante F, Sifola C. A biochemical method for the quantitation of myocardial scarring after experimental coronary artery occlusion. J Mol Cell Cardiol 1986; 18:283-290.
23. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem 1995; 147:29-34.
24. Schlüter C, Duchrow M, Wohlenberg C, Becker MHG, Key G, Flad H-D, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993; 123:513-522.
25. Gore SD, Weng L-J, Burke PJ. Validation of flow-cytometric determination of Ki67 expression as a measure of growth factor response in acute myelogenous leukemia. Exp Hematol 1993; 21:1702-1708.
26. The staining of mast cells. In: Sagher F, Even-Paz Z (editors): Mastocytosis and the mast cell. Chicago, Illinois: Year Book Medical Publishers; 1967, pp. 269-277.
27. Roberts ISD, Brenchley PEC. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol 2000; 53:858-862.
28. Brigstock DR, Steffen CL, Kim GY, Vegunta RK, Diehl JR, Harding PA. Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids. Identification as heparin-regulated Mr 10,000 forms of connective tissue growth factor. J Biol Chem 1997; 272:20275-20282.
29. Lim D-S, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103:789-791.
30. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'hern R, et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998; 48:107-116.
31. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Di Marco B, et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 1996; 16:3105-3110.
32. Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar LJ, et al. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 1994; 54:2073-2076.
33. Yang F, Yang X-P, Liu Y-H, Xu J, Rhaleb N-E, Peng H-M, et al. Effects of Ac-SDKP, a natural inhibitor of hematopoietic stem cell proliferation, on cardiac collagen deposition in rats with myocardial infarction [abstract]. Hypertension 2000; 36:703.
34. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariéty J, et al. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 1994; 70:286-294.
35. Nicoletti A, Heudes D, Mandet C, Hinglais N, Bariety J, Michel JB. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res 1996; 32: 1096-1107.
36. Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. In: Zanchetti A, Devereux RB, Hansson L, Gorini S. (editors): Hypertension and the heart, New York, NY: Plenum Press; 1997, pp. 35-44.
37. Kawanami O, Ferrans VJ, Fulmer JD, Crystal RG. Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab Invest 1979; 40:717-734.
38. Dvorak AM. Mast-cell degranulation in human hearts. N Engl J Med 1986; 315:969-970.
39. Sperr WR, Bankl HC, Mundigler G, Klappacher G, Grossschmidt K, Agis H, et al. The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood 1994; 84:3876-3884.
40. Kalsner S, Richards R. Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: a mechanism for coronary spasm. Science 1984; 223:1435-1437.
41. Forman MB, Oates JA, Robertson D, Robertson DM, Roberts LJ, II, Virmani R. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 1985; 313:1138-1141.
42. Kaartinen M, Penttila A, Kovanen PT. Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase-and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler Thromb 1994; 14:966-972.
43. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995; 92:1084-1088.
44. Vigorito C, Russo P, Picotti GB, Chiariello M, Poto S, Marone G. Cardiovascular effects of histamine infusion in man. J Cardiovasc Pharmacol 1983; 5:531-537.
45. Vigorito C, Poto S, Picotti GB, Triggiani M, Marone G. Effect of activation of the H1 receptor on coronary hemodynamics in man. Circulation 1986; 73:1175-1182.
46. Marone G, Giordano A, Cirillo R, Triggiani M, Vigorito C. Cardiovascular and metabolic effects of peptide leukotrienes in man. Ann NY Acad Sci 1988; 524:321-323.
47. Hartmann T, Ruoss SJ, Raymond WW, Seuwen K, Caughey GH. Human tryptase as a potent, cell-specific mitogen: role of signaling pathways in synergistic responses. Am J Physiol 1992; 262:L528-L534.
48. Baud L, Perez J, Denis M, Ardaillou R. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J Immunol 1987; 138:1190-1195.
49. Russel JD, Russell SB, Trupin KM. The effect of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue. J Cell Physiol 1977; 93:389-393.
50. Hatamochi A, Fujiwara K, Ueki H. Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin. Arch Dermatol Res 1985; 277:60-64.
51. Mukherjee D, Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest 1991; 88:1141-1146.
52. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-b1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 1995; 27:2347-2357.
53. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int 2002; 62:1149-1159.
54. Moussad EEA, Brigstock DR. Connective tissue growth factor: what's in a name? Mol Genet Metab 2000; 71:276-292.
55. Steffen CL, Ball-Mirth DK, Harding PA, Bhattacharyya N, Pillai S, Brigstock DR. Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro. Growth Factors 1998; 15:199-213.
56. Kanasaki K, Koya D, Sugimoto T, Isono M, Kashiwagi A, Haneda M. N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-β-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol 2003; 14:863-872.
57. Junot C, Nicolet L, Ezan E, Gonzales M-F, Menard J, Azizi M. Effects of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide Acetyl-Ser-Asp-Lys-Pro in rats. J Cardiovasc Pharmacol 1999; 291:982-987.
58. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, et al. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994; 24:195-204.
59. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed kidney of the rat. Kidney Int 1994; 45:1637-1647.